Skip to main content

Articles

Original Research, Practice Management

Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers

Burton S. Brodsky, MD; Gary M. Owens, MD; Dennis J. Scotti, PhD, MBA; Keith A. Needham, BS; Christina L. Cool, MPH

Stakeholder Perspective

Economic Impact of Using Tests to Guide the Treatment of Patients with Ovarian Cancer

F. Randy Vogenberg, PhD, RPh

ACR 2017, Conference Correspondent

Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA

ACR 2017, Conference Correspondent

Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA

ACR 2017, Conference Correspondent

Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA

ACR 2017, Conference Correspondent

Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA

ACR 2017, Conference Correspondent

Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA

ACR 2017, Conference Correspondent

Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA

ACR 2017, Conference Correspondent

Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment

ACR 2017, Conference Correspondent

Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs

ACR 2017, Conference Correspondent

Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis

Page 80 of 245
Results 791 - 800 of 2441